164 related articles for article (PubMed ID: 30337526)
1. BTK: a two-faced effector in cancer and tumour suppression.
Rada M; Barlev N; Macip S
Cell Death Dis; 2018 Oct; 9(11):1064. PubMed ID: 30337526
[TBL] [Abstract][Full Text] [Related]
2. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
3. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
[TBL] [Abstract][Full Text] [Related]
4. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH
Anticancer Res; 2020 Nov; 40(11):6093-6099. PubMed ID: 33109547
[TBL] [Abstract][Full Text] [Related]
6. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
Feng Y; Duan W; Cu X; Liang C; Xin M
Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
[TBL] [Abstract][Full Text] [Related]
7. Development of BTK inhibitors for the treatment of B-cell malignancies.
Kim HO
Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214
[TBL] [Abstract][Full Text] [Related]
8. Aberrantly expressed Bruton's tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells.
Pikatan NW; Liu YL; Bamodu OA; Hsiao M; Hsu WM; Haryana SM; Sutaryo ; Chao TY; Yeh CT
Cell Oncol (Dordr); 2020 Dec; 43(6):1067-1084. PubMed ID: 32705581
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase.
Buhl AM; Cambier JC
J Immunol; 1999 Apr; 162(8):4438-46. PubMed ID: 10201980
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
Diao Y; Fang X; Song P; Lai M; Tong L; Hao Y; Dou D; Liu Y; Ding J; Zhao Z; Xie H; Li H
Bioorg Med Chem; 2019 Aug; 27(15):3390-3395. PubMed ID: 31221612
[TBL] [Abstract][Full Text] [Related]
11. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
[TBL] [Abstract][Full Text] [Related]
12. BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses.
Althubiti M; Rada M; Samuel J; Escorsa JM; Najeeb H; Lee KG; Lam KP; Jones GD; Barlev NA; Macip S
Cancer Res; 2016 Sep; 76(18):5405-14. PubMed ID: 27630139
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases.
Li Z; Wahl MI; Eguinoa A; Stephens LR; Hawkins PT; Witte ON
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13820-5. PubMed ID: 9391111
[TBL] [Abstract][Full Text] [Related]
14. New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma.
Gomes S; Raimundo L; Soares J; Loureiro JB; Leão M; Ramos H; Monteiro MN; Lemos A; Moreira J; Pinto M; Chlapek P; Veselska R; Sousa E; Saraiva L
Cancer Lett; 2019 Apr; 446():90-102. PubMed ID: 30664963
[TBL] [Abstract][Full Text] [Related]
15. A Fast and Clean BTK Inhibitor.
Gabizon R; London N
J Med Chem; 2020 May; 63(10):5100-5101. PubMed ID: 32401033
[TBL] [Abstract][Full Text] [Related]
16. B cell receptor signaling down-regulates forkhead box transcription factor class O 1 mRNA expression via phosphatidylinositol 3-kinase and Bruton's tyrosine kinase.
Hinman RM; Bushanam JN; Nichols WA; Satterthwaite AB
J Immunol; 2007 Jan; 178(2):740-7. PubMed ID: 17202334
[TBL] [Abstract][Full Text] [Related]
17. Bruton's tyrosine kinase is essential for hydrogen peroxide-induced calcium signaling.
Qin S; Chock PB
Biochemistry; 2001 Jul; 40(27):8085-91. PubMed ID: 11434777
[TBL] [Abstract][Full Text] [Related]
18. Bruton's tyrosine kinase is required for signaling the CD79b-mediated pro-B to pre-B cell transition.
Kouro T; Nagata K; Takaki S; Nisitani S; Hirano M; Wahl MI; Witte ON; Karasuyama H; Takatsu K
Int Immunol; 2001 Apr; 13(4):485-93. PubMed ID: 11282988
[TBL] [Abstract][Full Text] [Related]
19. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
Sakthivel S; Habeeb SKM
J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
[TBL] [Abstract][Full Text] [Related]
20. BTK modulates p73 activity to induce apoptosis independently of p53.
Rada M; Barlev N; Macip S
Cell Death Discov; 2018; 4():30. PubMed ID: 30245853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
